Who is eligible for clinical trial NCT07581379?

Participants must meet protocol criteria for Lung Neoplasms. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07581379 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-05-06

Advancing Precision Lung Cancer Surveillance and Outcomes in Diverse Populations (NCT07581379)

🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: University of Florida

🩺 Plain-English Summary (8th-Grade Level)

This observational study evaluates the effectiveness of computed tomography (CT) imaging surveillance after curative-intent treatment for stage I-IIIA non-small cell lung cancer (NSCLC) in a diverse U.S. population. The main questions are: How do CT surveillance use and adherence vary by race, ethnicity, and socioeconomic status? Does semi-annual CT surveillance improve outcomes compared with annual surveillance? Adults ages 20-90 with stage I-IIIA NSCLC treated between 2012 and 2026 will be identified using OneFlorida+ electronic health records, tumor registry data, claims, and clinical notes. Patients will be followed for up to five years after curative-intent therapy to evaluate surveillance patterns, recurrence, second primary lung cancers, complications, and survival.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (9 items).

Location: University of Florida College of Medicine — Gainesville, Florida

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Adults diagnosed with primary, pathologically confirmed stage I-IIIA non- small cell lung cancer (NSCLC).
Received curative-intent therapy, including: Surgical resection, or Stereotactic body radiation therapy (SBRT), with or without adjuvant therapy.
Completed curative-intent therapy and survived at least 5 months after therapy initiation.
Received care within the University of Florida (Gainesville or Jacksonville) health system, and are included in the OneFlorida+ clinical data network.
Have available: Structured EHR data (including tumor registry linkage, imaging, procedures, and vital statistics), and Unstructured clinical documents (clinic notes, radiology reports, pathology reports) enable NLP extraction. \- Have ≥1 follow-up encounter in the EHR after treatment completion to allow surveillance assessment.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Histology other than NSCLC, including: Small-cell lung cancer Carcinoid tumors Rare non-NSCLC primary tumors
Metastatic disease (stage IV) at diagnosis.
No curative-intent therapy received (e.g., palliative treatment only).
Patients with incomplete treatment records prevent the determination of the treatment completion date.
Patients with no surveillance-relevant follow-up data, including: No post-treatment clinical notes No radiology/pathology records No linked tumor registry or vital status data
Patients with recurrence or who die within the first 5 months after starting curative-intent therapy (insufficient window for guideline-defined surveillance).
Patients with missing identifiers prevent linkage to cancer registries or the death index.
Individuals whose imaging cannot be classified as surveillance vs. diagnostic due to the absence of relevant structured or unstructured data.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

University of Florida College of Medicine — Gainesville, Florida

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗